Eli Lilly and Company

Jeremy Schulenburg York

Matthew Allen Schiffler

Yanping Xu

Owen Brendan Wallace

Steven Lee Kuklish

Alan M Warshawsky

Matthew Joseph Fisher

Rosanne Bonjouklian

Peter Rudolph Manninen

Alexei Pavlovych Krasutsky

Leonard Larry Winneroski, Jr

Nancy June Snyder

Brandon Lee Parkhurst

Katherine Marie Partridge

Jason Scott Sawyer

Douglas Wade Beight

Thomas Daniel Aicher

Vinod Francis Patel

Ho-Shen Lin

Brian Stephen Muehl

Bryan Hurst Norman

Michael Enrico Richett

Ronald Jay Hinklin

Kenneth Jeff Thrasher

Louis Nickolaus Jungheim

John Gordon Allen

William Thomas McMillen

Jefferson Ray McCowan

Julian Stanley Kroin

Jeffrey Daniel Cohen

Zhaogen Chen

Peter Ambrose Lander

Maria-Jesus Blanco-Pillado

Renhua Li

Junkai Liao

Gary A Hite

James Lee Toth

Joseph Michael Gruber

Ashraf Saeed

Tatiana Natali Vetman

Jonathan Michael Yingling

Rebecca Ruth Miles

Sreenivasarao Vepachedu

Douglas Webb Johnson

Mark Christopher Lohman

Isabel Cristina Gonzalez Valcarcel

Yongping Xie

Maria Jesus Blanco-Pillado

Keith Geoffrey Phillips

Sarah Katharina Fritschi

Shih-Ying Wu

Kaushambi Roy

Jibo Wang

Douglas Raymond Perkins

Andrew Peter McCarthy

Barbara Calamini

Qiupang Wang

Wesley Todd White

Gary Alan Hite

Junior Leonard Larry Winneroski

Provided herein are MAPT RNAi agents and compositions comprising a MAPT RNAi agent. Also provided herein are methods of using the MAPT RNAi agents or compositions comprising a MAPT RNAi agent for reducing MAPT expression and/or treating tauopathy in a subject.

MAPT RNA interference agents

The present invention provides a compound of the Formula I: wherein A is: and W, Y, X, R, R, R, and Rare as defined herein, or a pharmaceutically acceptable salt thereof, for use as an inhibitor of the EP4 receptor. 

Dimethylbenzoic acid compounds

The present invention provides compounds of Formula 1, or a pharmaceutically acceptable salts, thereof, where R, X, A, E, and G are as described herein, methods of preparing the compounds, and use of the compounds to treat pain and/or inflammation. 

Carboxylic acid compounds useful for inhibiting microsomal prostaglandin E2 synthase-1

The present invention provides compounds of Formula (1), or a pharmaceutically acceptable salt thereof, formula (1), where R, R1, and G are as described herein; methods of preparing the compounds; and use of the compounds to treat pain and/or inflammation associated with arthritis or osteoarthritis. 

[object Object]

The present invention provides a compound of the Formula (I): wherein X, R, R, R, R, R, R, R, R, R, and Rare as defined herein, or a pharmaceutically acceptable salt thereof. 

Phenoxyethyl cyclic amine derivatives and their activity as EP4 receptor modulators

The present invention provides a compound of the Formula II:  

Phenoxyethyl piperidine compounds

The present invention provides a compound of the Formula I: wherein R is H or F; or a pharmaceutically acceptable salt thereof. 

Phenoxyethyl dihydro-1H-isoquinoline compounds

The present invention provides compounds of the formula below or pharmaceutical salts thereof, wherein R1, R2 and R3 are as described herein; methods of treating osteoarthritis using the compounds; and a process for preparing the compounds.

Imidazole-2-benzamide compounds useful for the treatment of osteoarthritis

The present invention discloses novel compounds of Formula I: possessing 11 &#x3b2;-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11 &#x3b2;-HSD type 1 activity. 

Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

The present invention discloses novel compounds of Formula I: having 11&#x3b2;-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11&#x3b2;-HSD type 1 activity. 

Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

The present invention discloses novel compounds of Formula I: having 11&#x3b2;-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11&#x3b2;-HSD type 1 activity.

Piperidinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

The present invention discloses novel compounds of Formula I: (I) possessing 11&#x3b2;-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11&#x3b2;-HSD type 1 activity. 

Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR), such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases. 

Phenoxyether derivatives as PPAR modulators

Novel pyrazolopyridine derivative compounds are disclosed and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors useful in the treatment of cancer and other disease states influenced by TGF beta.

Pyrazolopyridine derivatives as pharmaceutical agents

Growing community of inventors

Noblesville, IN, United States of America

Jeremy Schulenburg York